JLE

European Journal of Dermatology

MENU

Cost analysis of individualised dosing of omalizumab for the treatment of patients with chronic urticaria Volume 33, numéro 5, September-October 2023

Tableaux

Auteurs
St. James’s Hospital UCARE centre, St. James’s Hospital, School of Medicine, Trinity College Dublin, Ireland

It is increasingly recognised that an individualised approach to treatment dosing with omalizumab severity may improve patient outcomes in patients living with chronic urticaria. This is reflected in the latest international urticaria guideline, which recognises varying treatment response thresholds to omalizumab [1, 2]. Individualised dosing has been shown to lead to reduced symptoms of urticaria, improved quality of life and decreased hospital visits [3]. However, the cost impact of this approach [...]